Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.

Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...

Under the terms of the deal, Bedford, Mass.-based Stoke (STOK) will retain exclusive rights for the treatment called zorevunersen in the U.S., Canada and Mexico, while Cambridge, Mass.-based Biogen ...

Multiple system atrophy (MSA) is a rare neurological disorder that leads to the progressive deterioration of nerve cells in ...

Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $207.00.

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...